Literature DB >> 8319190

Current role of gallium scan and magnetic resonance imaging in the management of mediastinal Hodgkin lymphoma.

M D Gasparini1, L Balzarini, M R Castellani, J D Tesoro Tess, L S Maffioli, R Petrillo, E Ceglia, R Musumeci, G L Buraggi.   

Abstract

BACKGROUND: A residual mediastinal mass after treatment represents a common diagnostic problem in the management of patients with Hodgkin lymphoma (HD). Conventional diagnostic radiology, computed tomography (CT), or ultrasonography (US) do not adequately reflect changes as fibrosis or necrosis. Gallium-67 (67Ga) imaging has been proven to be useful for the evaluation of HD in the mediastinum. The authors compared the ability of gallium scan and magnetic resonance imaging (MRI) to evaluate the mediastinal disease in the follow-up of patients with HD.
METHODS: Thirty-four patients previously treated for HD were investigated with gallium scan, MRI, and all the other investigations to evaluate the mediastinal region. Sixteen patients were in restaging after treatment, and 18 were investigated for suspected radiologic recurrence in the mediastinum (follow-up, 9-75 months). The results of gallium scan and MRI were matched with clinical findings during the follow-up.
RESULTS: A sensitivity of 85.7% for 67Ga and 92.8% for MRI was found, while the specificity was 100% for the scan and 80.6% for MRI. The predictive positive value that resulted was 100% for 67Ga and 68.4% for MRI.
CONCLUSIONS: Both examinations were accurate in assessing the activity of residual masses in the mediastinum after treatment. 67Ga showed a lower sensitivity in comparison with MRI, but 67Ga frequently overestimates the presence of pathologic tissue. The authors acknowledge the complementary role of these two tests, but if only one of these examinations can be performed for logistic or economic reasons, then gallium scan represents the single most adequate diagnostic procedure.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8319190     DOI: 10.1002/1097-0142(19930715)72:2<577::aid-cncr2820720240>3.0.co;2-1

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  5 in total

1.  Restaging with gallium scan identifies chemosensitive patients and predicts survival of poor-prognosis mediastinal Hodgkin's disease patients.

Authors:  I Ionescu; P Brice; D Simon; A Guermazi; T Leblanc; P Rousselot; D Gossot; V Meignin; C Gisselbrecht; J D Rain
Journal:  Med Oncol       Date:  2000-05       Impact factor: 3.064

2.  Magnetic resonance imaging and 67Ga scan versus computed tomography in the staging and in the monitoring of mediastinal malignant lymphoma: a prospective pilot study.

Authors:  M Bendini; C Zuiani; M Bazzocchi; G Dalpiaz; F Zaja; E Englaro
Journal:  MAGMA       Date:  1996 Sep-Dec       Impact factor: 2.310

3.  Comparison of technetium-99m methoxyisobutylisonitrile and gallium-67 citrate scanning in the assessment of lymphomas.

Authors:  P Ziegels; M Nocaudie; D Huglo; M Deveaux; L Detourmignies; E Wattel; X Marchandise
Journal:  Eur J Nucl Med       Date:  1995-02

Review 4.  The role of SPET and PET in monitoring tumour response to therapy.

Authors:  Chariklia Giannopoulou
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-06-14       Impact factor: 9.236

5.  MRI and PET in monitoring response in lymphoma.

Authors:  Alain Rahmouni; Alain Luciani; Emmanuel Itti
Journal:  Cancer Imaging       Date:  2005-11-23       Impact factor: 3.909

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.